CTX-439: A First-in-Class Orally Available CDK12 Inhibitor with Anti- Tumor Potential
Time: 8:30 am
day: Day Two
Details:
- Analyzing CTX-439's selective inhibition of CDK12 and its impact on transcription elongation, leading to aberrant RNA accumulation and increased cancer cell stress
- Evaluating the preclinical anti-tumor efficacy of CTX-439 in various carcinoma mouse models, assessing its potential as an effective single-agent therapy
- Exploring the synergistic effects of combining CTX-439 with PARP inhibitors or chemotherapeutic agents, focusing on enhanced DNA damage response and overall treatment efficacy
